Addgene Taps Industry Veteran for Commercial Push into Biopharma

WATERTOWN, Mass. – February 26, 2026 – Addgene, the nonprofit organization renowned for creating a global library of research tools for academic scientists, has appointed life sciences veteran Greg Crescenzi as its new Vice President of Global Commercial Strategy and Partnerships. The move signals a significant strategic evolution for the organization, aiming to leverage its trusted brand and vast repository to more deeply serve the fast-paced biopharmaceutical industry.

For over two decades, Addgene has built its reputation as a cornerstone of academic research, facilitating the sharing of over 170,000 plasmids, viral vectors, and antibodies. Now, by bringing in a leader with over 30 years of experience commercializing industry-first technologies, Addgene is making a deliberate push to bridge the gap between academic discovery and industrial application, positioning itself as a critical partner in the entire drug development pipeline.

A Strategic Pivot to Industry

Addgene's appointment of Crescenzi is the most visible sign yet of a strategy that has been quietly building for years. The organization is evolving from its primary role as a facilitator for academic labs to a more dynamic player that also meets the distinct needs of commercial entities, from fledgling startups to established pharmaceutical giants.

This strategic pivot comes at a time when the lines between academic innovation and commercial development are increasingly blurred. The rise of complex modalities like cell and gene therapies has created an unprecedented demand for high-quality, well-validated biological materials—the very resources Addgene has spent years curating.

“We are thrilled to welcome Greg to the Addgene team as we continue to broaden access to high-quality research tools that power scientific progress,” said Chonnettia Jones, PhD, President and Executive Director at Addgene, in a statement. “His leadership will be a key asset in our efforts to forge mission-aligned strategic partnerships that drive organizational growth, while scaling our offerings to academic and industry customers alike.”

This expansion is not about abandoning its core mission of scientific sharing but rather extending its reach. The organization aims to apply its successful model of centralized distribution, quality control, and community building to the commercial sector, accelerating research and development on a much broader scale.

The Commercialization Catalyst: Greg Crescenzi

To lead this charge, Addgene has chosen a leader whose career is defined by driving growth and commercializing cutting-edge life science technologies. Greg Crescenzi's extensive track record makes him a powerful catalyst for Addgene’s ambitions.

Before joining Addgene, Crescenzi served as CEO of Nirrin Technologies, where he was tasked with commercializing novel analytical systems for bioprocessing. His experience as Chief Commercial Officer at Kytopen is particularly relevant, where he led the commercial strategy for a non-viral gene delivery platform developed at MIT, a technology aimed at dramatically speeding up cell therapy manufacturing.

His tenure at Cytiva (formerly GE Healthcare Life Sciences) further highlights his expertise in scaling industrial solutions. Crescenzi was instrumental in establishing the Enterprise Solutions business and delivering the industry's first flexible CAR-T manufacturing platforms. He is known for taking innovative products from concept to market leadership, a skill set that aligns perfectly with Addgene’s goal of expanding its service offerings.

“This is an exciting time to join Addgene, as the organization continues to expand its tools available to industry partners,” Crescenzi stated. “The scientific community has long trusted Addgene to power their research in academic labs across the globe, and now they can continue to leverage a growing selection of our services in their role as industry innovators. I’m grateful to join a team committed to accelerating science and discovery – from academic to startup labs and beyond.”

Expanding the Arsenal: Beyond the Plasmid Repository

While its plasmid library remains the foundation, Addgene has been methodically expanding its arsenal to become a more comprehensive resource for industrial R&D. This strategic build-out of services and materials directly addresses the sophisticated needs of biopharma clients.

A key area of expansion is its viral vector services. Building on its service that launched in 2016, Addgene recently introduced "Packaged on Request" in January 2025. This service allows customers to select from over 3,000 AAV plasmids and have them packaged into specific viral serotypes on demand. This provides the flexibility and customization crucial for therapeutic development, backed by Addgene’s rigorous quality control, including ddPCR titering and viral genome sequencing.

The organization has also made significant inroads into the recombinant antibody space since 2022, addressing a critical industry need for reliable and reproducible reagents. Through strategic partnerships, such as its collaboration with the Institute for Protein Innovation (IPI), Addgene is distributing validated antibodies with available sequence data, helping to combat the reproducibility crisis that plagues both academic and industrial research.

Furthermore, a July 2025 partnership with Promega to launch the Promega Plasmid Collection marked another milestone. The initiative not only provided researchers with 300 plasmids for bioluminescent assays crucial for drug discovery but also introduced purified DNA as a new product format for Addgene, demonstrating a clear response to industry preferences for ready-to-use materials.

Navigating a Competitive Landscape

In its push into the commercial space, Addgene enters a highly competitive arena dominated by established giants like Thermo Fisher Scientific, Lonza, and Catalent. These companies operate as large-scale Contract Development and Manufacturing Organizations (CDMOs) and tool suppliers, offering end-to-end solutions, often under GMP (Good Manufacturing Practice) conditions required for clinical trials.

However, Addgene is not positioning itself as a direct competitor to these CDMOs. Instead, its strategy appears to leverage its unique strengths to carve out a distinct niche. Its value proposition is built on a foundation of trust, quality, and unparalleled access to a diverse catalog of tools sourced directly from the forefront of academic innovation. While a CDMO offers scale and GMP compliance, Addgene offers a vast, searchable library of discovery tools that can accelerate the earliest and most critical stages of R&D.

The organization’s purpose-driven model and deep roots in the scientific community provide a unique advantage. For startups and innovation hubs within larger biopharma companies, Addgene represents a cost-effective and efficient way to access a wide array of validated materials without the logistical hurdles of sourcing from individual academic labs. Its expansion during the COVID-19 pandemic, where it made over 90% of its relevant plasmids available to industry, showcased its agility and commitment to accelerating science in a crisis—a powerful demonstration of its potential as an industry partner.

Crescenzi's appointment is a clear indicator that Addgene is ready to formalize and scale these industry relationships. His role will be to build the commercial infrastructure that allows Addgene to serve its new customer segment effectively while preserving the mission-driven culture that has made it an indispensable resource for scientists worldwide. This balancing act will be crucial as Addgene navigates its next chapter of growth, transforming scientific sharing into a powerful engine for therapeutic innovation.